Investigation of KRAS and NRAS expression levels in lung cancer patients compared to normal patients

Lung cancer is one of the most common cancers around the world, and a major cause of death. The KRAS and NRAS genes could cause malfunction in signal transduction and cell cycle regulation. In this study, the expression level of KRAS and NRAS biomarkers among 50 lung cancer patients in comparison with 50 normal individuals was investigated. Total RNA from blood samples was extracted and the cDNA synthesized. The specific primers for detection of markers were designed and the expression levels of KRAS and NRAS genes in the presence GAPDH using the qRT-PCR method were quantitatively studied. Quantitative comparison showed that KRAS and NRAS expression levels increased significantly in lung cancer patients compared to the control population. Results showed a quantitative increase of KRAS and NRAS genes with an increase of 2/05 and 3/43 fold respectively, for lung cancer compared to normal samples. Based on current study results, we could quantitatively predict the expression level of KRAS and NRAS genes in patients which could be used as a biomarker indicator during screening of lung cancer samples. This could also be used as a noninvasive method for the screening of the population for early detection to inhibit cancer